Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Celldex+Therapeutics+%28CLDX%29+Reports+Publication+of+Glembatumumab+Vedotin+Phase+12+Studies+in+JCO/9872613.html for the full story.
NEW YORK, April 14, 2011 (GLOBE NEWSWIRE) -- The JETS Contrarian Opportunities Index Fund (NYSE:JCO) celebrated the one-year anniversary of its NYSE ARCA listing on April 8, 2011. The Exchange Traded Fund (ETF) is the first to follow a dynamic,
The steady rise in the number of exchange-traded products available to U.S. investors over the last several years has been primarily driven not by duplication, but by innovation. The vast majority(...)Read the rest of Contrarian And Momentum ETFs...
JETS Dow Jones Islamic Market International Index Fund (JVS), having failed to attract investor assets, will cease trading on October 19, 2010. The fund had just $2.2 million at the end of last month, which is about the same as when it...
PRINCETON, N.J., Sept. 16, 2010 (GLOBE NEWSWIRE) -- Javelin Investment Management has announced that its JETS Dow Jones Islamic Market International Index Fund (NYSEArca:JVS) will cease trading on October 19, 2010. Launched on July 1, 2009, the fund
Oops! Unable to complete your request. Please refresh your browser.
The article on this fund has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.